Abstract
CAR T-cell therapy is a recent therapeutic advancement that has transformed the management of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). To date, there are 2 FDA-approved CAR-T products for R/R B-ALL: tisagenlecleucel in patients aged,26 years and brexucabtagene autoleucel in those aged $18 years. This review summarizes the pivotal clinical trials that led to FDA approval of these 2 products and highlight emerging data addressing key questions pertinent to CAR-T utilization in the rapidly evolving landscape of R/R ALL management. These include optimal sequencing of CAR-T among other novel immunotherapeutic agents, the role of consolidation and maintenance following CAR-T, novel CAR-T constructs currently under clinical development, and strategies to optimize use of commercially available CAR-T products to improve patient outcomes.
Original language | English (US) |
---|---|
Article number | e247065 |
Journal | JNCCN Journal of the National Comprehensive Cancer Network |
Volume | 22 |
Issue number | 8 |
DOIs | |
State | Published - Oct 2024 |
ASJC Scopus subject areas
- Oncology